NECTAR: A 12-month double-blind randomized controlled pivotal trial to evaluate the safety and efficacy of endoluminal Aluvra(TM) for the treatment of gastroesophageal reflux disease
G
Glen Lehman, MD
Primary Investigator
Not Recruiting
22 years - 100 years
All
Phase
N/A
1 Location
Brief description of study
This study will be conducted to evaluate whether Alvura?, a carbon coated bead mixture (soft tissue bulking agent) injected in the area of your esophagus in an area called the lower esophageal sphincter (LES) can improve your symptoms of reflux and/or decrease your need for medication to manage your gastroesophageal reflux.
Detailed description of study
The purpose of this study is to evaluate the safety and efficacy of Aluvra for the treatment of patients suffering from GERD who experience inadequate symptom relief despite treatment with GERD medication for at least six months.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: gastroesophageal reflux disease
-
Age: 22 years - 100 years
-
Gender: All
Updated on
01 Aug 2024.
Study ID: 1703665506
